On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- US, European Pharma Groups Push LDP to Expedite Vaccine Policies
November 22, 2019
- Upper House Panel Discusses PMD Law Amendment Bill, Another Session Set for Nov. 26
November 22, 2019
- MHLW Proposes 3-Stage Plan to Develop Systems to Promote Genomic Medicine for Intractable Diseases
November 22, 2019
- Chuikyo Discussing Admission Fee for Schizophrenia Patients on Drug Clozapine, Eyeing Transition to Home
November 21, 2019
- MHLW to Propose “Special Rule” for Indication Change Re-Pricing
November 21, 2019
- Japan Grants Orphan Status to Tepotinib and More
November 20, 2019
- 83 ADR Reports from Patients Received in 4 Months after March Launch of New Reporting System: MHLW
November 20, 2019
- Regenerative Medicine Industry Calls for Appropriate Reward for Innovation: Public-Private Confab
November 19, 2019
- MHLW Panel to Discuss Eisai’s Insomnia Med and More on Nov. 29, Skips Ono’s Cachexia Drug Again
November 18, 2019
- Inpatient Generic Use Tops 80% in Japan Hospitals: Chuikyo
November 18, 2019
- 8.2% of Hospitals Have Formularies: Chuikyo Survey
November 18, 2019
- MHLW Orders Label Revisions for Xtandi, Erleada to Include Interstitial Lung Disease to ADR List
November 18, 2019
- Lower House OKs PMD Law Amendment Bill
November 15, 2019
- Will Japan Reinstate Sakigake Status for Aducanumab? Many See It Unlikely
November 15, 2019
- Only 2.4% of Pharmacies Have Generic Drug Formularies in Their Region: Tokyo Govt Survey
November 15, 2019
- PMD Law Amendment Bill Clears Lower House Health Panel
November 14, 2019
- Forteo, Enbrel Biosimilars OK’ed for Self-Injection; Evrenzo under Flat-Fee System
November 14, 2019
- Chuikyo Rep Calls for Modifying Re-Pricing Criteria with Eye to Xolair’s Pollen Allergy Use
November 14, 2019
- Panel OKs Orphan Status for 3 Cell, Gene Therapies
November 14, 2019
- Astellas’ HIF-PH Inhibitor, Trintellix, Venclexta, and Many More OK’ed for Listing on Nov. 19
November 13, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…